As many of you have heard, we are launching a strategic planning process for the Cancer Center. We are required to do this for the Cancer Center Support Grant (CCSG), and it is also an opportunity to take a careful look at where we are and where we want to go. As part of the planning process, we will examine our research programs and identify research questions that deserve further attention. For example, it is very likely that we will decide to commit more resources and attention to the constellation of obesity, metabolism, cancer, and behavioral interventions. We have considerable expertise in each of these areas, and it is widely appreciated that the obesity epidemic is playing an increasing role in cancer causation and cancer-associated morbidity and mortality. We plan to choose a number of different topics/research questions that will form a major focus of our work in the next 5-7 years. In addition, we will ask what resources are needed (e.g., tumor banking, enhanced informatics, project management) to fulfill our translational potential.

On the clinical side, we will have a similar process. To identify clinical programs that should be expanded or developed, we will consider the following three questions: 1) Are there clinical programs that are needed to address the cancer burden in our catchment area? 2) Are there clinical programs that need further development to meet our goals as a comprehensive cancer center? 3) Are there areas that should be expanded to enhance our ability to conduct translational research? As an example, hepatocellular cancer is increasing in incidence in Connecticut, and we may well want to focus incremental clinical resources in this area. Similarly, there is a growing population of cancer survivors, and we may want to expand our services for this group of patients, both to meet their clinical needs and to address research questions in health care delivery, late toxicities, and the psychosocial sequelae of cancer treatment.

Finally, much of the strategic plan will center on our need to build community outreach and engagement. Connecticut is faced with a major problem related to cancer care disparities. There is huge variation in socioeconomic status in our state and this leads to unequal cancer care and outcomes. To address this, we are building subspecialty oncology practices across the state. Providing outstanding care close to home is a first step in eradicating disparities, but alone it is insufficient. We need to reach out to communities facing health care challenges and disparities. We are fortunate that Marcella Nunez-Smith is leading our efforts in community outreach. Under her leadership, we hope to expand our efforts in underserved communities. Whenever possible, we will use evidence-based approaches.
communities. Whenever possible, we will use evidence-based approaches that have been shown to be successful, and we will accumulate additional evidence about how we can help provide the best cancer care to all who need it.

As the strategic planning process unfolds over the next month, I will update you regularly on the progress and you should expect a final report mid-fall. I am energized to have this process underway and believe it will not only make our CCSG grant strong, but far more importantly, it will make Yale Cancer Center and the Smilow Enterprise even stronger. I am always happy to hear suggestions from any of you…my door and email are open.

Have a wonderful weekend and a great upcoming holiday weekend. It is finally summer. Be well.

**Eric**

---

**Announcements**

**New Physicians to Join Smilow Cancer Network**

Michael Grant, MD, and So Yeon Kim, MD, will join the Smilow Cancer Hospital Care Centers in Waterbury and North Haven, respectively, as of August 1. Dr. Grant received his medical degree from the Albert Einstein School of Medicine and did his residency in Internal Medicine at Duke University School of Medicine. He recently completed his fellowship at Yale School of Medicine during which he was enrolled in the Yale Cancer Center T32 Advanced Training Program for Physician-Scientists. Dr. Kim received her medical degree from the Albert Einstein School of Medicine and completed her residency at Tufts Medical Center. She recently graduated from fellowship at the Montefiore Medical Center.

Dr. Grant will be appointed an Assistant Professor of Medicine (Medical Oncology) and will care for patients with thoracic and genitourinary malignancies in Waterbury. His current research interests include targeted and immunotherapy approaches to the treatment of non-small cell lung cancer (NSCLC). In 2021, he received the ASCO Conquer Cancer Young Investigator Award to study sensitivity and resistance to EGFR-targeted therapies in patients with NSCLC harboring certain EGFR mutations.

Dr. Kim will be an Assistant Professor of Medicine (Medical Oncology) and will focus her clinical practice on the care of patients with thoracic cancers. 

---

**Top Takeaways in Lung Cancer From ASCO 2022 — Our roundtable of experts each offer two studies they believe to be most impactful**

---

**Breast Friends Fund raises money for breast cancer research**

---

**Smilow Shares Survivorship Series: Fear of Cancer Recurrence**

---

**Watch Now**
will focus her clinical practice on the care of patients with thoracic cancers. In 2021, Dr. Kim received the Second Place Hussein M. Abdel-Dayem, MD Award for Abstract with Highest Scientific Merit at the Society of Nuclear Medicine and Molecular Imaging Annual Northeast Regional Scientific Meeting. Her ongoing research projects are focused on NSCLC.

---

**Notables**

**Marie Robert, MD**, Professor of Pathology and Medicine (Digestive Diseases), Director of Gastrointestinal and Liver Pathology, has been honored with a **Yale Medicine Distinguished Clinical Career Award**. Dr. Robert is an internationally-recognized gastrointestinal, liver, and pancreatic surgical pathologist. She has more than 30 years of experience in clinical diagnosis, teaching, and collaborative scientific endeavors across a wide spectrum of diseases, including inflammatory and neoplastic conditions of the GI tract.

**Michael Girardi, MD**, an internationally-recognized investigator and translational expert in the advancement of personalized therapy for cutaneous T cell lymphoma (CTCL), was recently appointed the **Evans Professor of Dermatology**. Dr. Girardi is a member of Yale Cancer Center’s Cancer Immunology Research Program.

**Cynthia James, MBA, CPC, CRHC**, Clinical Department Liaison for Yale Cancer Center at Smilow Cancer Hospital, was recently honored by the **Charter Oak State College Board of Regents** with an honorary degree, **Doctor of Humane Letters**. Cynthia was highlighted for her contributions to the College and her professional accomplishments at Smilow Cancer Hospital, where her dedication to patient care and compassion are authentic and personal. Cynthia also serves on the Diversity Equity and Inclusion Committee of the American College of Healthcare Executives/Connecticut Chapter.

**Yale New Haven Children’s Hospital (YNHCH)**, the top-ranked children’s hospital in Connecticut, has been ranked among the best children’s hospitals in the nation for eight out of ten pediatric subspecialties in the **2022-23 Best Children’s Hospitals** rankings, published online today by U.S. News & World Report. YNHCH ranked #45 in the nation for cancer care.

**John Lewin, MD, FSBI**, Breast Imaging Division Chief in the Department of Radiology and Biomedical Imaging, has been elected **President of the Society of Breast Imaging**.

**Elizabeth Berger, MD, MS**, Assistant Professor of Surgery (Surgical Oncology) and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, was presented with the **C. Elton Cahow Teaching Award for Outstanding Faculty Teaching** by Mehra Golshan, MD, MBA, during Yale Surgery’s annual awards program. The award honors the faculty member who has contributed the most to the education of the junior residents.

**Ronald Salem, MD, FACS, FRSC (Ed), FRCS(C), MBChB**, Lampman Professor of Surgery (Surgical Oncology), was presented with the **Edward H. Storer Award by the Department of Surgery**. The award is the oldest and most prestigious in the Department of Surgery, created in 1939 by Dr. Storer in honor of his father, Dr. Henry Storer, who was an early pioneer in surgery.

---

Follow us!
The H. Storer Award by the Department of Surgery. The award is the oldest and most prestigious award in the department and recognizes the outstanding teaching of Dr. Storer, long-time chief at the VA Hospital. The recipient is selected by the graduating chief residents. Dr. Salem shared the award with Dr. Melissa Perkal.

Maryam Lustberg, MD, MPH, Associate Professor of Medicine (Medical Oncology) and Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, has been named to the Cancer Health 25 list in recognition of her work to improve the long-term side effects for patients with breast cancer and her broader vision of supportive care for all patients and survivors of cancer.

Pamela Kunz, MD, Associate Professor of Medicine (Medical Oncology) and Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, has been awarded the Wendy U. and Thomas C. Naratil Pioneer Award by Women's Health Research at Yale to study sex-based differences in adverse events associated with treating neuroendocrine neoplasms.

Mariya Rozenblit, MD, has been promoted to Assistant Professor of Medicine (Medical Oncology) effective July 1, 2022. Dr. Rozenblit cares for patients with breast cancer through the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center in New Haven and in Greenwich.

Susan G. Komen announced new research grants to support breast cancer research at Yale Cancer Center, including funding to support Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology) and Co-Leader of the Genetics, Genomics, and Epigenetics Research Program, and Mariya Rozenblit, MD. Dr. Pusztai will study, “Characterizing the Immune System and Discovering New Treatments in Primary and Metastatic Breast Cancers” and Dr. Rozenblit will focus on, “Curing de novo stage IV oligometastatic HER2+ breast cancer.”

The Genetics, Genomics, and Epigenetics Research Program welcomes He (Peter) Wang, MD, PhD, Associate Professor of Pathology. Dr. Wang has in-depth understanding of human disease biomarkers, at fluid, cellular and histologic levels and has a long-term interest in smoking-related health effect and biomarkers. Dr. Wang’s lab is focused on studies of biological effects of E-cigarette, including mtDNA damage, systematic inflammation biomarkers, atherosclerosis, combined effects of E-cigarette and Vitamin E on lung damage, and tumor metastasis, both in animal models and in human subjects.

James Farrell, MD, along with Ankit Chhoda, MD, recently contributed to an exciting study, “The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival,” published in the Journal of Clinical Oncology. Within the multicenter Cancer of Pancreas Screening-5 (CAPS5) study, which Drs. Farrell and Chhoda led locally at Yale, annual imaging surveillance and MRI was performed on individuals who were determined to be high-risk for pancreatic cancer. It was concluded that most pancreatic cancers diagnosed within the study group in the recent years had stage I disease with long-term survival.

An internationally recognized expert in pancreatic disease treatment and research, Dr. Farrell is known for his development of personalized therapy approaches for pancreatic cancer and early detection biomarkers for pancreatic cancer. In addition to his clinical work, Dr. Farrell leads the Pancreatic Cancer Early Detection Clinic, part of The Smilow Cancer Genetics and Prevention Program, which provides personalized consultations, genetic counseling, and a personalized care plan for patients who are determined to be high risk for pancreatic cancer.

We are thankful for the leadership of Dr. Farrell and his efforts to advance the early detection of pancreatic cancer, the third most deadly cancer in the United States.
Diversity, Equity, and Inclusion

50th Anniversary of Title IX
On June 23, we celebrated the 50th anniversary of the passage of Title IX of the Education Amendments Act of 1972: “No person in the United States shall, on the basis of sex, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any education program or activity receiving Federal financial assistance.”

Title IX had a profound effect on women’s access to medical education in the United States. While Elizabeth Blackwell graduated from Geneva Medical College in 1849, as the first woman to complete formal medical training in the U.S., access to medical schools remained very difficult for women. Blackwell’s remarkable career in medicine and public health was also marked by her commitment to medical education for women, most easily accomplished in those years by founding independent women’s medical colleges. Yale admitted its first three women students in 1916 and by 1960, the last holdout (Jefferson Medical College) was also accepting women.

However, until the passage of Title IX, quotas limiting the enrollment of women students were widespread. Class action suits brought under Title IX were largely settled in the late 1970s, and the first classes with 50% representation of women began matriculating in the early 1980s. The success women have achieved in medicine and medical science – the breakthroughs resulting from their scholarship, the high standard of the care they deliver, their commitment to mentorship – has greatly enriched our profession. The explicit biases still present when some of us began our training have left their mark, and there is still work to do to ensure that the bright young women who bring their passion, their great grades, and their hard work to medicine, find all the opportunity they deserve.

DEI Climate Survey
Yale Cancer Center and Smilow Cancer Hospital are committed to building a diverse and welcoming community. To help us achieve our goals, we ask you to participate in our climate survey, to let us hear about your experiences and your view of diversity, equity, and inclusion. The data will be analyzed by an independent consultant (The Barthwell Group), and your answers will remain completely anonymous. We urge you to be candid – only by truly understanding barriers faced by some in our community will we be able to dismantle those barriers. The results will be most meaningful with high participation.

The survey for Yale Cancer Center members, trainees, and employees launched on June 15th by email from Dr. Winer’s office. Access to the survey will be with a link embedded in the survey. Please take these few minutes to make sure we hear your voice!

Sing Her Name

Read More
Join the Yale Working Women’s Network and Yale African American Affinity Group for a two-part book event about *Sing Her Name: A Novel*. Follow the path of two musically gifted women whose lives overlap across the boundaries of time. The book club discussion will take place on Monday, July 11 from 12:30-1:30pm via Zoom. **Register for book club discussion.** The book talk with Rosalyn Story will take place on Monday, July 18 from 12-1pm via Zoom. **Register for book talk.**

---

**Employee Profile: Julie Baker**

![Leukemia and Lymphoma APP Team (l to r): Alfredo Axtmayer, Lisa Barbarotta, Ethan Kohn, Julie Baker, Kait Dolan, and Erin Medoff (not pictured: Jean Vollmer)](image)

Julie Baker, MSN, APRN, has been with the Hematology Program at Smilow Cancer Hospital and Yale Cancer Center for 17 years and cares for patients on the outpatient leukemia service. She began her nursing career with the Stem Cell Transplant Program, and now sees patients undergoing active treatment for chronic and acute leukemias and myelodysplasia. In 2019, Julie received the Ruth McCorkle Advanced Practice Provider Award in recognition of her compassionate care for her patients.

Depending on the diagnosis, treatments can be complicated or more straightforward, but either way they require dedication and commitment to the treatment and supportive care processes on behalf of the patient and their provider. “People presenting with these diagnoses demand empathy, honesty, and concentrated clinical care. We are upfront with our patients from the start and work with them closely to manage side effects from the disease and treatments,” said Julie. “Our service works in tandem with the stem cell transplant team, as many patients will require a bone marrow transplant. It is an arduous process for people, and a comprehensive team approach is what we provide.”

Julie also commented that although the treatment process can be intense, there is currently a lot happening in terms of research, including immune-mediated and molecularly targeted therapies, and Yale is at the forefront of these efforts. For decades, no new drugs were available to patients with leukemia, and that is changing rapidly. Julie will be departing Yale this July.

---

Congratulations to Benjamin L. Judson, MD, MBA, on his appointment as the Charles W. Ohse Professor of Surgery (Otolaryngology) at Yale School of Medicine!

![Benjamin L. Judson, MD, MBA, appointed the Charles W. Ohse Professor of Surgery (Otolaryngology) at Yale School of Medicine](image)

---

Nikhil Joshi, PhD, Assistant Professor of Immunobiology and a member of Yale Cancer Center’s Cancer Immunology Research Program, is a recipient of the 2022 Pershing Square Sohn Prize for Young Investigators in Cancer Research. The prize provides early career, New York area scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking.

![Nikhil Joshi, PhD, awarded 2022 Pershing Square Sohn Prize for Young Investigators in Cancer Research](image)

---

Volunteers needed! Smilow Cancer Hospital is asking patients with breast cancer who have had a mastectomy without reconstruction and are at least 18 years old to participate in a confidential research study investigating the experience of loss of one or both breasts from breast cancer surgery. If you enroll, you will be asked to participate in an interview about your experience following surgery.

![Volunteers needed! Smilow Cancer Hospital is asking patients with breast cancer who have had a mastectomy without reconstruction and are at least 18 years old to participate in a confidential research study investigating the experience of loss of one or both breasts from breast cancer surgery. If you enroll, you will be asked to participate in an interview about your experience following surgery.](image)
leukemia, and that is changing rapidly. Julie will be departing Yale this July. Her colleagues provided the following thoughts:

“Julie is trusted and beloved by her patients, treasured by her colleagues, and sought out by trainees for her wisdom. She is a role model for compassionate and expert care and we are so grateful for everything she does.” - Stephanie Halene, MD, PhD

“Julie has been the backbone of the hematology clinic. She has touched so many lives throughout the years, from easing the distress of a new diagnosis through supporting a patient and family in the last days of a loved one’s life. She has brought compassion and expertise to all she does. She is a guiding light for all of us and will be sorely missed. Her departure ends an era that cannot be replaced.” - Erin Medoff, APRN

Recent Publications


Knowlton CA, Jimenez RB, Moran MS. Risk Assessment in the Molecular Era Seminars in Radiation Oncology, 32(3):189-197.


Clinic, established in 2006, was the first dedicated, multidisciplinary resource for cancer survivors in the State of Connecticut to provide patients and their families with vital information on cancer prevention, wellness, supportive services, and the latest health research related to cancer survivorship. The Survivorship Clinic provides dedicated support services for patients, including personalized wellness education and follow-up planning; psychosocial support for survivors and their families; nutritional counseling; exercise and fitness recommendations; and specialized team care, recognizing the importance of taking care of the whole person – through all phases of care, including survivorship.

If you are interested in Clinic services and would like to schedule an appointment, please call (203) 785-CARE.

A recent study from @elizabethprsic @TCarafeno @JennyXiangMD and Hari Deshpande, MD, showed how timely, post-discharge #medonc appts can significantly reduce 30-day readmission and ED visits.

Today we congratulate @maryam_lustberg, director of the Breast Center at @smilowcancer and Chief of Breast Medical Oncology at @yalecance, as she is appointed President of @cancercaremascc.

A recent study from @elizabethprsic @TCarafeno @JennyXiangMD and Hari Deshpande, MD, showed how timely, post-discharge #medonc appts can significantly reduce 30-day readmission and ED visits.

Today we congratulate @maryam_lustberg, director of the Breast Center at @smilowcancer and Chief of Breast Medical Oncology at @yalecance, as she is appointed President of @cancercaremascc.
Schukken KM, Sheltzer J. 
**Extensive Protein Dosage Compensation in Aneuploid Human Cancers**  
*Genome Research*, Online ahead of print.  
Read More

**Correction: Genomic Profiling Of Sporadic Multiple Meningiomas**  
Read More

Xiang J, Chow R, Reynoso A, Carafeno T, Deshpande H, Strait M, Prsic E.  
**Association between Postdischarge Medical Oncology Follow-up Appointments and Downstream Health Care Use: A Single-institution Experience**  
*JCO Oncology Practice*, Online ahead of print.  
Read More

Khdtir M, El Annan T, El Amine MA, Shareef M.  
**Complications of Lymphoma In The Abdomen And Pelvis: Clinical And Imaging Review**  
*Abdominal Radiology*, Online ahead of print.  
Read More

Chaudhary S, Roy A, Summers C, Zhornitsky S, Ahles T, Li CR, Chao HH.  
**Hypothalamic Connectivities Predict Individual Differences in ADT-elicted Changes in Working Memory and Quality of Life in Prostate Cancer Patients**  
*Scientific Reports*, 12(1):9567.  
Read More

Buza N, Hui P.  
**Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma**  
*Archives of Pathology and Laboratory Medicine*, 146(5):0.  
Read More

**Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL**  
Read More

---

**Funding and Award Opportunities**

**NCCN and AstraZeneca Quality Improvement Initiative: Improving the Quality of Care and Application of Best Practices in the Treatment of Patients with Small Cell Lung Cancer (SCLC) Research Grant Opportunity**  
The intent of this RFP is to encourage NCCN Member Institutions to submit proposals that propose a research project focused on quality improvement in the treatment of patients with SCLC.  
Read More

---

---

---

---

---

---

---
LOIs describing concepts and ideas for evaluating barriers to guideline concordant care in LS-SCLC and/or ES-SCLC and developing healthcare quality improvement initiatives to enhance patient care and outcomes.

**Letter of Intent Due:** June 27, 2022

**2022 Yale Cancer Center Internal Pilot Grants Competition**

These grants will support all potential areas of innovative cancer research including basic, clinical, computational, population and epidemiology, prevention/control, implementation science and translational cancer research. Relevance of proposed research to our catchment area priorities is also an important consideration.

The YCC Center for Community Engagement and Health Equity is available for consultation on community engagement, health disparities, and catchment relevance (Jessica.Lewis@yale.edu).

**Application Deadline:** July 1, 2022

**Damon Runyon Cancer Research Foundation: Runyon-Rachleff Innovation Award 2022**

This award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

**Internal Deadline:** July 1, 2022

**Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)**

This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

**Application Deadline:** July 5, 2022

**Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01/R21)**

This FOA solicits grant applications proposing to utilize bacteria, archaeabacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics.

**Application Deadline:** July 5, 2022

**Cancer Control Research in Persistent Poverty Areas (U54)**

Through this FOA, the NCI invites applications for Cancer Control Research in Persistent Poverty Areas (Persistent Poverty Initiative). The goal is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas.

**Application Deadline:** July 6, 2022

**Endocrinology Clinical Dilemma**

June 24; 12:00 PM

Carolina Gonzalez-Lopez

**Yale Cancer Answers**

June 26; 7:30 PM

NPR

Advancing our Understanding of Gastrointestinal Diseases

Stavroula Hatzios, PhD

**Smilow Shares**

June 29; 6:30 PM

Patient & Family Cancer Survivor Series: Shop Savvy for Survivors—Eat healthy on a budget


**Urology Times Case-Based Roundtable**

June 29; 8:00 PM

Emerging Approaches in Metastatic Prostate Cancer

Dr. Jason Hafron

**Calendar**

Endocrinology Clinical Dilemma
June 24; 12:00 PM

Carolina Gonzalez-Lopez

Learn More

Yale Cancer Answers
June 26; 7:30 PM

NPR

Advancing our Understanding of Gastrointestinal Diseases

Stavroula Hatzios, PhD

Learn More

Smilow Shares
June 29; 6:30 PM

Patient & Family Cancer Survivor Series: Shop Savvy for Survivors—Eat healthy on a budget


Learn More

Urology Times Case-Based Roundtable
June 29; 8:00 PM

Emerging Approaches in Metastatic Prostate Cancer

Dr. Jason Hafron

Learn More
Pancreatic Cancer Research Program
The FY22 Defense Appropriations Act provides funding for the Pancreatic Cancer Research Program (PCARP) to support research of exceptional scientific merit and innovation with high impact that focuses on pancreatic cancer. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
- Idea Development Award
- Translational Research Partnership Award
Preproposals Due: July 8, 2022
Read More

DoD Melanoma Research Program Awards
These awards invest in research focusing on the prevention, detection, diagnosis, and treatment of melanoma for the benefit of Service members, Veterans, their families, and the American public.
- Focused Program Award – Rare Melanomas – Letter of Intent Due: September 14, 2022
- Melanoma Academy Scholar Award – Letter of Intent Due: September 14, 2022
- Mid-Career Accelerator Award – Letter of Intent Due: September 14, 2022
- Team Science Award – Letter of Intent Due: September 14, 2022
- Idea Award – Preproposal Due: July 8, 2022
Read More

The Mark Foundation for Cancer Research: 2023 Mark Foundation Endeavor Award
These awards support teams of scientists with diverse areas of expertise to address urgent problems in cancer research. The Endeavor Award program enables teams of three or more investigators to tackle challenges in cancer research that are too large for any single lab to address alone. Endeavor Awards are $3 million grants disbursed over a three-year term.
Internal Deadline: July 13, 2022
Read More

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)
The purpose of this FOA is to invite applications for TCORS to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the Research Objectives related to the regulatory authority of the FDA Center for Tobacco Products.
Application Deadline: July 14, 2022
Read More

Damon Runyon Cancer Research Foundation: Damon Runyon-Dale F. Frey Award for Breakthrough Scientists 2022
The Damon Runyon Fellowship identifies the nation’s top postdoctoral fellows and provides funding that enables them to complete their training under the mentorship of a leading senior scientist and encourages them to follow their own bold ideas. To catapult their research careers—and their impact on cancer—the Foundation will make an additional investment in these exceptional individuals by selecting them as recipients of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists.
Internal Deadline: July 15, 2022
Read More

Share your news!
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications
Innovations for Veterans QuickFire Challenge: Lung Cancer & Physical Trauma
Innovators are invited to submit potentially ground-breaking ideas that aim to directly address the unique healthcare needs of the military community including lung cancer and physical trauma.
Application Deadline: July 15, 2022

DoD Breast Cancer Research Program Transformative Breast Cancer Consortium Award
This award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.
Pre-application Due: August 3, 2022

DoD Breast Cancer Research Program Awards
These awards provide funding to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members, Veterans, and the general public.
- **Breakthrough Award Levels 1 and 2** - LOI Due: September 22, 2022
- **Breakthrough Award Level 3** - Pre-application Due: August 3, 2022
- **Breakthrough Award Level 4** - Pre-application Due: August 3, 2022
- **Era of Hope Scholar Award** - LOI Due: September 22, 2022
- **Innovator Award** - LOI Due: August 3, 2022

DoD Ovarian Cancer Research Program Clinical Trial Award
This award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.
Application Deadline: August 5, 2022

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44)
This FOA solicits SBIR applications from small business concerns that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency.
Application Deadline: August 6, 2022

Gabrielle's Angel Foundation
The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment. Of interest are innovative clinical and basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies. Focus is on projects for cancer prevention, detection and treatment that are most likely to be translated into clinical trials within a 3-5 year period.
Internal Submission Deadline: August 8, 2022
AACR-Lung Cancer Initiative at Johnson & Johnson - Stimulating Therapeutic Advances through Research Training (START)
These grants, which will provide support to postdoctoral or clinical research fellows from underrepresented groups combine research experiences in both academic and industry settings, following a research timeline that will be of greatest benefit to the proposed work.
Application Deadline: August 18, 2022

Small Business Transition Grant For Early Career Scientists (R42)
Through this FOA, the NCI, National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Drug Abuse (NIDA) intend to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses.
Application Deadline: August 22, 2022

CRI Irvington Postdoctoral Fellowship and the Postdoctoral Fellowship to Promote Racial Diversity
CRI Fellowships further career development and support laboratory research for promising young scientists working under the mentorship of leading immunologists. CRI is seeking hypothesis-driven, mechanistic studies in both fundamental immunology and tumor immunology that aim to directly impact our understanding of the immune system’s role in cancer.
Application Deadline: September 1, 2022

Limited Competition: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research (U24)
The purpose of this limited competition FOA is to continue support for the Center for International Blood and Marrow Transplant Research (CIBMTR) as a data resource enabling broad studies on Hematopoietic Stem Cell transplantation (HCT) and Adoptive Cellular Therapy (ACT) research.
Application Deadline: September 15, 2022

DoD Rare Cancers Research Program Awards
There are a significant number of incidences of rare cancers in the U.S. military population. Over 60 forms of cancer disproportionately impact those who have served in the military, and 67% of them are rare cancers. These awards support research on the prevention, detection, diagnosis, and treatment of Service Members, Veterans, their families, and the American public.
- Concept Award - Application Deadline: August 29, 2022
- Idea Development Award - Application Deadline: September 30, 2022
- Resource and Community Development Award - Application Deadline: September 30, 2022

DoD Kidney Cancer Research Program (KCRP)
These awards support research of exceptional scientific merit in the area of kidney cancer.
- Academy of Kidney Cancer Investigators Early-Career Scholar Award - LOI Due: September 29, 2022
- Nurse-Initiated Research Award - LOI Due: September 29, 2022